
A BILL FOR AN ACT

RELATED TO CONTROLLED SUBSTANCES.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. The legislature finds that in recent years a
2 growing variety of cannabis products, including those containing
3 delta-8-tetrahydrocannabinol (delta-8 THC), have gained
4 significant prevalence in Hawaii, leading to increased public
5 use and commercial availability of these products. Delta-8 THC
6 has been marketed as a legal alternative to traditional
7 cannabis, despite similar psychoactive properties between the
8 two.

9 The legislature further finds that the widespread
10 availability and use of delta-8 THC and similar cannabinoids
11 have raised concerns about consumer safety, labeling accuracy,
12 potential health risks, and the need for appropriate regulatory
13 oversight. Current state laws have not sufficiently addressed
14 the growing market of these new cannabis-derived compounds,
15 leaving gaps in regulation and enforcement. It is therefore
16 necessary for state law to evolve in response to the changing



1 landscape of cannabis products, ensuring both consumer
2 protection and public safety.

3 Accordingly, the purpose of this Act is to amend the
4 definitions of "artificially derived cannabis", "cannabis", and
5 "manufactured hemp product" under the hemp processors law to
6 include all forms of cannabinoids classified as schedule I under
7 the Uniform Controlled Substances Act.

8 SECTION 2. Section 328G-1, Hawaii Revised Statutes, is
9 amended as follows:

10 1. By amending the definition of "artificially derived
11 cannabinoid" to read:

12 ""Artificially derived cannabinoid" means a chemical
13 substance, including any of the substances enumerated in section
14 329-14(g), that is created by a chemical reaction that changes
15 the molecular structure of any chemical substance derived from
16 the plant genus cannabis. "Artificially derived cannabinoid"
17 does not include:

18 (1) A naturally occurring chemical substance that is
19 separated from the plant genus cannabis by a chemical
20 or mechanical extraction process; or



1 (2) Cannabinoids that are produced by decarboxylation from
2 naturally occurring cannabinoid acid without the use
3 of a chemical catalyst."

4 2. By amending the definition of "cannabis" to read:

5 ""Cannabis" means the genus of the flowering plant in the
6 family Cannabaceae. For the purpose of this chapter, cannabis
7 refers to any form of the plant where the delta-9
8 tetrahydrocannabinol concentration on a dry weight basis has not
9 yet been determined. "Cannabis" includes any of the substances
10 enumerated in section 329-14(g)."

11 3. By amending the definition of "manufactured hemp
12 product" to read:

13 ""Manufactured hemp product" means a product created by
14 processing, as defined in this chapter, that:

15 (1) Is either:

16 (A) Intended to be consumed orally to supplement the
17 human or animal diet in tablet, capsule, powder,
18 softgel, gelcap, or liquid form (e.g., hemp oil);

19 or

20 (B) In a form for topical application to the skin or
21 hair;



1 (2) Does not include any living hemp plants, viable seeds,
 2 leaf materials, [~~o~~] floral materials[~~r~~], synthetic
 3 cannabinoids, or artificially derived cannabinoids;
 4 and

5 (3) Includes any other product specified by the department
 6 pursuant to section 328G-4(a)(7)."

7 SECTION 3. Section 329-14, Hawaii Revised Statutes, is
 8 amended by amending subsection (g) to read as follows:

9 "(g) Cannabinoids. Unless specifically excepted or unless
 10 listed in another schedule, any of the following cannabinoids,
 11 including their salts, isomers, and salts of isomers, whenever
 12 the existence of these salts, isomers, and salts of isomers is
 13 possible within the specific chemical designation:

14 (1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
 15 naturally contained in a plant of the genus Cannabis
 16 (cannabis plant), as well as synthetic equivalents of
 17 the substances contained in the plant, or in the
 18 resinous extractives of Cannabis, sp. or synthetic
 19 substances, derivatives, and their isomers with
 20 similar chemical structure and pharmacological
 21 activity to those substances contained in the plant,



- 1 such as the following: Delta 1 cis or trans
2 tetrahydrocannabinol, and their optical isomers; Delta
3 6 cis or trans tetrahydrocannabinol, and their optical
4 isomers[?] (other names: Delta 8 cis or trans
5 tetrahydrocannabinol, and their optical isomers); and
6 Delta 3,4 cis or trans-tetrahydrocannabinol, and its
7 optical isomers (since nomenclature of these
8 substances is not internationally standardized,
9 compounds of these structures, regardless of numerical
10 designation of atomic positions, are covered);
- 11 (2) Naphthoylindoles; meaning any compound containing a 3-
12 (1-naphthoyl)indole structure with substitution at the
13 nitrogen atom of the indole ring by a alkyl,
14 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
15 1-(N-methyl-2-piperidinyl)methyl or 2-(4-
16 morpholinyl)ethyl group, whether or not further
17 substituted in the indole ring to any extent and
18 whether or not substituted in the naphthyl ring to any
19 extent;
- 20 (3) Naphthylmethylindoles; meaning any compound containing
21 a 1H-indol-3-yl-(1-naphthyl) methane structure with



1 substitution at the nitrogen atom of the indole ring
2 by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
3 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
4 2-(4-morpholinyl) ethyl group whether or not further
5 substituted in the indole ring to any extent and
6 whether or not substituted in the naphthyl ring to any
7 extent;

8 (4) Naphthoylpyrroles; meaning any compound containing a
9 3-(1-naphthoyl)pyrrole structure with substitution at
10 the nitrogen atom of the pyrrole ring by a alkyl,
11 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
12 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)
13 ethyl group whether or not further substituted in the
14 pyrrole ring to any extent, whether or not substituted
15 in the naphthyl ring to any extent;

16 (5) Naphthylmethylindenes; meaning any compound containing
17 a naphthylideneindene structure with substitution at
18 the 3-position of the indene ring by a alkyl,
19 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
20 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
21 ethyl group whether or not further substituted in the



- 1 indene ring to any extent, whether or not substituted
2 in the naphthyl ring to any extent;
- 3 (6) Phenylacetylindoles; meaning any compound containing a
4 3-phenylacetylindole structure with substitution at
5 the nitrogen atom of the indole ring by a alkyl,
6 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
7 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
8 ethyl group whether or not further substituted in the
9 indole ring to any extent, whether or not substituted
10 in the phenyl ring to any extent;
- 11 (7) Cyclohexylphenols; meaning any compound containing a
12 2-(3-hydroxycyclohexyl) phenol structure with
13 substitution at the 5-position of the phenolic ring by
14 a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
15 cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
16 2-(4-morpholinyl) ethyl group whether or not
17 substituted in the cyclohexyl ring to any extent;
- 18 (8) Benzoylindoles; meaning any compound containing a 3-
19 (benzoyl) indole structure with substitution at the
20 nitrogen atom of the indole ring by a alkyl,
21 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,



- 1 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
2 morpholinyl) ethyl group whether or not further
3 substituted in the indole ring to any extent and
4 whether or not substituted in the phenyl ring to any
5 extent;
- 6 (9) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
7 pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-
8 naphthalenylmethanone (another trade name is WIN
9 55,212-2);
- 10 (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-
11 methyloctan-2-yl)-6a,7,10,10a-
12 tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
13 HU-210/HU-211);
- 14 (11) Tetramethylcyclopropanoylindoles; meaning any compound
15 containing a 3-tetramethylcyclopropanoylindole
16 structure with substitution at the nitrogen atom of
17 the indole ring by an alkyl, haloalkyl, cyanoalkyl,
18 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
19 methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl,
20 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
21 morpholinyl)methyl, or tetrahydropyranylmethyl group,



- 1 whether or not further substituted in the indole ring
2 to any extent and whether or not substituted in the
3 tetramethylcyclopropyl ring to any extent;
- 4 (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
5 its optical, positional, and geometric isomers, salts,
6 and salts of isomers (Other names: APINACA, AKB48);
- 7 (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
8 optical, positional, and geometric isomers, salts, and
9 salts of isomers (Other names: PB-22; QUPIC);
- 10 (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
11 carboxylate, its optical, positional, and geometric
12 isomers, salts, and salts of isomers (Other names: 5-
13 fluoro-PB-22; 5F-PB-22);
- 14 (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
15 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
16 positional, and geometric isomers, salts, and salts of
17 isomers (Other names: AB-FUBINACA);
- 18 (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
19 indazole-3-carboxamide, its optical, positional, and
20 geometric isomers, salts, and salts of isomers (Other
21 names: ADB-PINACA);



- 1 (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
2 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its
3 optical, positional, and geometric isomers, salts, and
4 salts of isomers (Other names: AB-CHMINACA);
- 5 (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
6 indazole-3-carboxamide, and geometric isomers, salts,
7 and salts of isomers (Other names: AB-PINACA);
- 8 (19) [1-(5-fluoropentyl)-1H-indazol-3-yl] (naphthalen-1-
9 yl)methanone, and geometric isomers, salts, and salts
10 of isomers (Other names: THJ-2201);
- 11 (20) Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-
12 valinate, and geometric isomers, salts, and salts of
13 isomers (Other names: FUB-AMB, Methyl 2-(1-(4-
14 fluorobenzyl)-1H-indazole-3-carboxamido)-3-
15 methylbutanoate, MMB-FUBINACA, AMB-FUBINACA);
- 16 (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
17 carboxamido)-3-methylbutanoate, and geometric isomers,
18 salts, and salts of isomers (Other names: 5-fluoro-
19 AMB, 5-fluoro-AMP);
- 20 (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
21 indazole-3-carboxamide, and geometric isomers, salts,



- 1 and salts of isomers (Other names: AKB48 N-(5-
2 fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
3 analog, 5F-APINACA);
- 4 (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
5 geometric isomers, salts, and salts of isomers (Other
6 names: STS-135, 5F-APICA; 5-fluoro-APICA);
- 7 (24) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
8 carboxylate, and geometric isomers, salts, and salts
9 of isomers (Other names: NM2201; CBL2201);
- 10 (25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
11 (cyclohexylmethyl)-1H-indazole-3-carboxamide, and
12 geometric isomers, salts, and salts of isomers (Other
13 names: MAB-CHMINACA and ADB-CHMINACA);
- 14 (26) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
15 carboxamido]-3,3-dimethylbutanoate (Other names: 5F-
16 ADB, 5-fluoro-ADB, and 5F-MDMB-PINACA), its optical,
17 positional, and geometric isomers, salts, and salts of
18 isomers;
- 19 (27) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-
20 3-carboxamide, its optical, positional, and geometric
21 isomers, salts, and salts of isomers (Other names:



- 1 SGT-78; 4-CN-CUMYL BINACA; 4-CN-CUMYL-BUTINACA; CUMYL-
2 CB-PINACA; CUMYL-CYBINACA; 4-cyano-CUMYL-BUTINACA;
3 CUMYL-4CN-BINACA);
- 4 (28) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
5 fluoropentyl)-1H-indazole-3-carboxamide (Other name:
6 5F-AB-PINACA);
- 7 (29) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-
8 carboxamido)-3-methylbutanoate (Other names: MMB-
9 CHMICA; AMB-CHMICA);
- 10 (30) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
11 pyrrolo[2,3-b]pyridine-3-carboxamide (Other names:
12 5F-CUMYL-P7AICA);
- 13 (31) Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-
14 3-carboxamido)butanoate (MDMB-4en-PINACA);
- 15 (32) Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
16 carboxamido)-3,3-dimethylbutanoate (Other name: 5F-
17 EDMB-PINACA);
- 18 (33) Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-
19 3,3-dimethylbutanoate (Other names: 5F-MDMB-PICA; 5F-
20 MDMB-2201);



1 (34) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
2 carboxamide (Other names: FUB-AKB48; FUB-APINACA;
3 AKB48 N-(4-FLUOROBENZYL));

4 (35) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-
5 indazole-3-carboxamide (Other names: 5F-CUMYL-PINACA;
6 SGT-25); and

7 (36) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-
8 tetramethylcyclopropyl)methanone (Other name: FUB-
9 144)."

10 SECTION 4. Statutory material to be repealed is bracketed
11 and stricken. New statutory material is underscored.

12 SECTION 5. This Act shall take effect on July 1, 3000.



Report Title:

Hemp Products; Uniform Controlled Substances Act; Schedule I;
Cannabinoids

Description:

For purposes of the hemp processors law, amends the definitions of "artificially derived cannabis" and "cannabis" to include, and the definition of "manufactured hemp product" to specifically exclude, all forms of cannabinoids classified as schedule I under the Uniform Controlled Substances Act. Effective 7/1/3000. (HD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

